Legend Biotech's LB2501 Hits 100% Response Rate in Early NHL Trial
Event summary
- Legend Biotech's LB2501 achieved 100% ORR and 83.3% CR rate in Phase 1 trial for relapsed/refractory B-cell NHL.
- Single infusion of LB2501 showed dose-dependent CAR-T expansion without lymphodepletion.
- No dose-limiting toxicities or serious adverse events reported; CRS and IRR were Grade 1–2.
- Results presented in late-breaking session at EHA 2026 Congress.
- LB2501 is a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy.
The big picture
Legend Biotech's LB2501 represents a significant step in the evolution of CAR-T therapies, offering a potential first-in-class in vivo approach that simplifies treatment by eliminating the need for lymphodepletion. The strong early data positions Legend Biotech as a leader in next-generation cell therapies, building on its existing success with CARVYKTI. The results could reshape the competitive landscape for relapsed/refractory B-cell NHL treatments, particularly if the safety and efficacy profile holds in larger studies.
What we're watching
- Clinical Validation
- Whether LB2501 can sustain its high response rates in larger, more diverse patient populations.
- Regulatory Pathway
- The pace at which Legend Biotech advances LB2501 through subsequent clinical phases.
- Competitive Positioning
- How LB2501's in vivo approach differentiates it from existing CAR-T therapies in the NHL space.
Related topics